statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit...

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024. In the first quarter of 2024, we have successfully completed a...

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access...

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

2seventy bio (TSVT Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on April 5. Analyst Samantha Semenkow...

Buy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic Outlook

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) have announced that on April 4, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel...

U.S. FDA Approves Bristol Myers Squibb and 2seventy bios Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (APA) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all...

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

2seventy bio, Inc. (NASDAQ:TSVT  Get Free Report) Director Casdin Capital, Llc acquired 330,000 shares of 2seventy bio stock in a transaction that occurred on Monday, March 25th. The stock was...

2seventy bio, Inc. (NASDAQ:TSVT) Director Buys $1,673,100.00 in Stock

2seventy bio, Inc. (NASDAQ:TSVT  Get Free Report) Director Casdin Capital, Llc acquired 300,000 shares of the stock in a transaction that occurred on Thursday, March 21st. The shares were...

2seventy bio, Inc. (NASDAQ:TSVT) Director Purchases $1,470,000.00 in Stock

2seventy bio, Inc. (NASDAQ:TSVT  Get Free Report) Director Casdin Capital, Llc purchased 330,000 shares of the businesss stock in a transaction dated Monday, March 25th. The shares were...

Casdin Capital, Llc Acquires 330,000 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

In trading on Monday, shares of 2seventy bio Inc (TSVT) crossed above their 200 day moving average of 5.28, changing hands as high as 5.57 per share. 2seventy bio Inc shares are currently...

Bullish Two Hundred Day Moving Average Cross - TSVT

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Watchers	13,959
52-Wk Low	$1.54
52-Wk High	$12.69

Volume	295,038.00
52-Wk High	$12.69
52-Wk Low	$1.54

TSVT 2seventy bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community